Adoptive cell therapies in oncology: a look at IMA203 and beyond

Allison Betof Warner, MD, PhD, Stanford Medicine, highlights the recent progress in adoptive cell therapies, with FDA approvals of TILs and T-cell receptor (TCR) therapies in 2024. The upcoming IMA203 trial (NCT03686124) is particularly promising, with genetic engineering of TILs and TCRs being explored to enhance efficacy and reduce toxicity. As cell therapy advances, researchers are investigating mechanisms of resistance and predictive biomarkers, aiming to improve treatment selection and outcomes for refractory melanoma patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.